Quick Answer
BioXcel Therapeutics, Inc. reported Net Income of -$69.90 million for fiscal year 2025.
BioXcel Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$69.90M | -17.3% |
| 2024 | -$59.60M | +66.7% |
| 2023 | -$179.05M | -8.0% |
| 2022 | -$165.76M | -55.0% |
| 2021 | -$106.93M | -30.1% |
| 2020 | -$82.17M | -149.2% |
| 2019 | -$32.97M | -71.1% |
| 2018 | -$19.27M | -324.5% |
| 2017 | -$4.54M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.91M | -126.5% | -61.1% |
| June 30, 2025 | -$19.19M | -131.2% | -164.5% |
| March 31, 2025 | -$7.25M | +72.9% | +46.9% |
| September 30, 2024 | -$13.65M | +73.0% | -64.5% |
| June 30, 2024 | -$8.30M | +84.5% | +69.0% |
| March 31, 2024 | -$26.79M | +49.3% | +46.9% |
| September 30, 2023 | -$50.49M | -20.8% | +5.7% |
| June 30, 2023 | -$53.52M | -42.1% | -1.4% |
- BioXcel Therapeutics, Inc. showed a decrease of -17.3% in Net Income compared to the prior fiscal year.
- Over the 2017–2025 period, BioXcel Therapeutics, Inc.’s net income has declined by 1439.9% (from -$4.54 million to -$69.90 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: